Levetiracetam

Elepsia, Keppra, Levetiracetam, Spritam (levetiracetam) is a small molecule pharmaceutical. Levetiracetam was first approved as Elepsia on 1999-11-30. It is used to treat epilepsy, juvenile myoclonic epilepsy, partial epilepsies, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A. Keppra's patents are valid until 2034-03-14 (FDA).